8-KAcquisitions & DispositionsExhibits & Filings

ABBOTT LABORATORIES 8-K Report, Acquisition Completed (Sep 26, 2014)

Filed September 26, 2014For Securities:ABT

Summary

Abbott Laboratories (ABT) announced on September 26, 2014, the successful completion of its acquisition of approximately 99.6% of CFR Pharmaceuticals S.A. This acquisition was executed through a purchase transaction and two tender offers, one targeting U.S. holders and the other targeting holders in Chile, for both ordinary shares and American Depositary Shares (ADSs) of CFR Pharmaceuticals. The transaction marks a significant expansion for Abbott into the Latin American market. The acquisition, valued at approximately $2.9 billion and funded through existing cash reserves, positions Abbott to leverage CFR Pharmaceuticals' established presence and comprehensive product portfolio across 15 countries in Latin America. CFR Pharmaceuticals specializes in branded generics, with strengths in therapeutic areas such as women's health, central nervous system, cardiovascular, and respiratory diseases, which are expected to complement Abbott's existing offerings and drive future growth.

Key Highlights

  • 1Abbott Laboratories has completed the acquisition of approximately 99.6% of CFR Pharmaceuticals S.A.
  • 2The acquisition was finalized on September 26, 2014, following tender offers in the U.S. and Chile.
  • 3The total consideration for the acquisition was approximately $2.9 billion.
  • 4Abbott funded the entire acquisition cost using its on-hand cash.
  • 5CFR Pharmaceuticals is a leading branded generics company with operations in 15 Latin American countries.
  • 6The acquisition strengthens Abbott's presence and product portfolio in the strategically important Latin American region.
  • 7Key therapeutic areas for CFR Pharmaceuticals include women's health, central nervous system, cardiovascular, and respiratory diseases.

Frequently Asked Questions

The primary purpose of this 8-K filing was to announce the completion of Abbott Laboratories' acquisition of CFR Pharmaceuticals S.A. and provide key details regarding the transaction.

The acquisition of CFR Pharmaceuticals is strategically significant as it provides Abbott with a strong foothold and established presence in the rapidly growing Latin American market, leveraging CFR's existing operations across 15 countries and its branded generics portfolio.

Abbott financed the approximately $2.9 billion acquisition entirely through its existing cash reserves, indicating a strong liquidity position at the time of the transaction.

CFR Pharmaceuticals is a branded generics pharmaceutical company with a diverse product portfolio covering multiple therapeutic areas, including women's health, central nervous system, cardiovascular, and respiratory diseases.